The abstract is read at the publisher; the summary is JClub's.
Once-weekly petrelintide in adults without type 2 diabetes produced a mean bodyweight reduction of -7·9% to -9·4% at 28 weeks versus -1·7% with placebo.
- Why it matters: Long-term obesity treatments are needed beyond incretin-based approaches, with clear efficacy and safety data for sustained dosing.
- What they did: In a multicentre, randomised, double-blind, placebo-controlled phase 2 trial across 32 sites in Poland, Romania, and the USA, 485 participants received at least one dose of once-weekly subcutaneous petrelintide (1·0–9·0 mg) or placebo for 42 weeks.
- The result: At 28 weeks, estimated treatment differences versus placebo ranged from -6·2% to -8·1%, and nausea was more common with petrelintide (20% vs 6%) with no deaths reported, supporting further long-term evaluation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.